Axsome Therapeutics
Axsome Therapeutics' revenue rose 65.5% to $638 million in fiscal 2025. Its operating margin was −26.1%, up from −72.7% a year earlier. Free cash flow was −$94 million. The diluted share count rose 3.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Axsome Therapeutics does
Axsome Therapeutics is a drug company focused on medicines for conditions of the central nervous system, meaning the brain and nerves. It sells three products approved by the FDA: Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness linked to sleep apnea or narcolepsy, and Symbravo for the acute treatment of migraine in adults.
It earns money by selling those three products. Their combined revenue was $638.5 million in 2025, up 66% from 2024. It also develops other drug candidates, which earn nothing until they win approval.
Its lead candidate, AXS-05, is being studied for agitation linked to Alzheimer's disease and for smoking cessation. In December 2025 the FDA accepted its application for the Alzheimer's agitation use and set a target decision date of April 30, 2026. Solriamfetol, the medicine in Sunosi, is in late-stage trials for ADHD, depression with sleepiness, binge eating disorder and shift work sleepiness.
Its biggest risks, as it describes them
- Continued losses since it began, with no promise it will ever be profitable.
- Its loan agreement with Blackstone restricts its activities and requires it to keep minimum cash.
- Dependence on the success of its products, with no guarantee that its candidates will finish trials or win approval.
- Lengthy, unpredictable FDA review that could delay or block new medicines.
- Only a short history of selling products, which makes its prospects harder to judge.
Income statement
Axsome Therapeutics lost money in fiscal 2025: a net loss of $183 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 86 | 201 | 386 | 315 | 323 |
| Debt incl. finance leases | 49 | 94 | 178 | 185 | 194 |
| Net debt (negative means net cash) | −37 | −107 | −208 | −130 | −128 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 3.1x | 0.9x | 0.9x | 3.2x | 2.2x |
| Interest coverage | −27.0x | −18.6x | −11.6x | −13.0x | −10.5x |
| Current ratio | 3.8x | 2.5x | 3.6x | 2.1x | 1.6x |
| Quick ratio | 3.8x | 2.5x | 3.5x | 2.0x | 1.5x |
Cash flow
Projections
Project Axsome Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Axsome Therapeutics shares on the open market, and 8 insiders sold $112.5 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Mark L. JacobsonChief Operating Officer | Sold plan | 10,000 | $208.65 | $2.1 million | Form 4 |
| Aug 6, 2026 | Herriot TabuteauChief Executive Officer, Director, 10% owner | Sold plan | 4,660 | $213.95 | $997,007 | Form 4 |
| Aug 5, 2026 | Herriot TabuteauChief Executive Officer, Director, 10% owner | Sold plan | 45,004 | $212.01 | $9.5 million | Form 4 |
| Jul 1, 2026 | Herriot TabuteauChief Executive Officer, Director, 10% owner | Sold plan | 49,666 | $240.25 | $11.9 million | Form 4 |
| Jun 11, 2026 | Roger JeffsDirector | Sold plan | 286 | $249.12 | $71,248 | Form 4 |
| Jun 10, 2026 | Mark ColemanDirector | Sold plan | 643 | $249.00 | $160,107 | Form 4 |
| Jun 10, 2026 | Susan MahonyDirector | Sold plan | 300 | $246.18 | $73,854 | Form 4 |
| Jun 10, 2026 | Roger JeffsDirector | Sold plan | 286 | $246.18 | $70,407 | Form 4 |
| Jun 9, 2026 | Herriot TabuteauChief Executive Officer, Director, 10% owner | Sold plan | 49,670 | $241.01 | $12.0 million | Form 4 |
| Jun 9, 2026 | Nick PizzieChief Financial Officer | Sold plan | 33,000 | $240.09 | $7.9 million | Form 4 |
| Jun 9, 2026 | Susan MahonyDirector | Sold plan | 300 | $237.21 | $71,163 | Form 4 |
| Jun 2, 2026 | Mark ColemanDirector | Sold plan | 5,537 | $223.39 | $1.2 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 8 | 3 of 8 | 4 of 8 |
| Rule of 40 | — | 9.2% | 50.8% |
| Altman Z'' | −2.70 | −6.70 | −5.64 |
| Accruals ratio | −20.5% | −27.5% | −14.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 5 of 8 | 3 of 8 | 4 of 8 |
Compare
Put Axsome Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics | FY25 | 65.5% | −26.1% | −14.7% | — | — | 4 | |
| OPKO Health | FY25 | −14.9% | −19.4% | −31.4% | −7.0% | — | 4 | Compare |
| Insmed | FY25 | 66.7% | −205.6% | −159.6% | — | — | 5 | Compare |
| Ultragenyx Pharmaceutical | FY25 | 20.2% | −79.5% | −70.1% | — | — | — | Compare |
| Kiniksa Pharmaceuticals | FY25 | 60.1% | 11.4% | 20.1% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | 0 | 271 | 386 | 638 |
| Revenue growth | — | — | — | — | — | — | — | — | 42.5% | 65.5% |
| Gross profit | — | — | — | — | — | — | −5 | — | — | — |
| Research and development | 21 | 20 | 24 | 54 | 70 | 58 | 58 | 98 | 187 | 183 |
| Operating income | −28 | −27 | −33 | −67 | −99 | −125 | −180 | −232 | −281 | −167 |
| Net income | −27 | −29 | −31 | −68 | −103 | −130 | −187 | −239 | −287 | −183 |
| Diluted EPS (US$) | −1.42 | −1.27 | −1.15 | −2.01 | −2.77 | −3.47 | −4.60 | −5.27 | −5.99 | −3.68 |
| Diluted shares (millions) | 19 | 23 | 27 | 34 | 37 | 38 | 41 | 45 | 48 | 50 |
| Cash flow | ||||||||||
| Cash from operations | −21 | −26 | −30 | −46 | −78 | −108 | −116 | −145 | −128 | −93 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Free cash flow | −21 | −26 | −30 | −46 | −78 | −109 | −117 | −146 | −129 | −94 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 53 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 2 | 6 | 15 | 21 | 38 | 63 | 85 | 94 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 37 | 34 | 14 | 220 | 184 | 86 | 201 | 386 | 315 | 323 |
| Debt incl. finance leases | 10 | 10 | 7 | 20 | — | 49 | 94 | 178 | 185 | 194 |
| Total assets | 38 | 36 | 15 | 220 | 186 | 88 | 332 | 588 | 568 | 690 |
| Total liabilities | 17 | 19 | 14 | 42 | 72 | 72 | 222 | 397 | 512 | 602 |
| Shareholders' equity | 22 | 17 | 1 | 179 | 114 | 16 | 110 | 191 | 57 | 88 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | −85.7% | −72.7% | −26.1% |
| Net margin | — | — | — | — | — | — | — | −88.4% | −74.5% | −28.7% |
| Free cash flow margin | — | — | — | — | — | — | — | −53.8% | −33.4% | −14.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | 9.2% | 50.8% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −80.0% | −151.2% | −350.8% | −76.1% | −70.4% | −201.5% | −299.0% | −159.2% | −231.6% | −252.1% |
| Return on assets | −62.3% | −78.5% | −121.6% | −57.9% | −50.6% | −95.2% | −89.3% | −52.0% | −49.7% | −29.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |